Source: Annual Congress 2001 - Lung cancer biology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Kotantoula, M. Fotinou, K. Papadopoulou, E. Tziralidis, H. Lambrakis, A. Paspali, M. Stoca, N. Georgatou, A. Papacharalambous (Athens, Greece). P-glycoprotein (p-gp) and lung resistance protein (lrp), as predictive factors of response to platinum-based chemotherapy for lung cancer. Eur Respir J 2001; 16: Suppl. 31, 1598

Member's Comments

No comment yet.

Related content which might interest you: The role of Pgp, MRP and LRP expression in chemotherapy response of small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Changes in the expression of Glutathione S Transferase-π (GST-π) and P-glycoprotein (P-gp) in bronchoscopic specimen of patients with lung cancer before and after chemotherapy Source: Eur Respir J 2001; 18: Suppl. 33, 231s Year: 2001 ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003 The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 The development of mutant P53 characterized by lung cancers contributes to their primary and acquired multi-drug resistance to chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Co-expression of S100A14 and S100A16 is a predictive marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinomas Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Genotyping single-nucleotide polymorphisms (SNP) in ERCC1, XPD, XRCC1, XRCC3 and MDR-1 and CCND-1 genes for response and toxicity prediction in chemotherapy of non small cell lung cancer (NSCLC) Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011